503A vs. 503B compounding | GLP-1 Clinics Nearby

503A

Patient-specific pharmacy pathway

503B

FDA-registered outsourcing facility

FDA-approved product

Neither

At a glance

503A and 503B at a glance

The practical difference is a regulatory pathway—not a marketing grade or a promise that a specific product is appropriate.

Swipe horizontally to compare →

503A and 503B at a glance. The practical difference is a regulatory pathway—not a marketing grade or a promise that a specific product is appropriate.
Comparison point	Section 503A	Section 503B
Who compounds	A licensed pharmacist in a state-licensed pharmacy or federal facility, or a licensed physician	A facility where compounding occurs by or under the direct supervision of a licensed pharmacist
Patient-specific prescription	Generally required for an identified individual patient, with limited anticipatory compounding	May or may not obtain prescriptions for identified individual patients
CGMP requirements	Exempt when all applicable 503A conditions are met	Required; 503B drugs are not exempt from CGMP
Primary oversight	State boards handle much day-to-day pharmacy oversight; FDA can inspect in surveillance or for-cause situations	FDA registration, risk-based inspection, product reporting, and adverse-event reporting apply
What the label does not mean	The compounded drug is not FDA approved	Registration does not mean FDA has found the facility compliant or approved its compounded drugs

Table source:FDA comparison of sections 503A and 503B

503A and 503B describe the compounder’s federal pathway

FDA’s current comparison of sections 503A and 503B explains two sets of conditions under the Federal Food, Drug, and Cosmetic Act. Section 503A generally applies to patient-specific compounding by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. Section 503B applies to an outsourcing facility that elects to register with FDA and meets that section’s conditions.

Neither pathway turns a compounded drug into an FDA-approved product or an FDA-approved generic. The broader compounded GLP-1 medication guide explains why product identity and current legal context still matter after the compounder’s category is known.

The prescription and quality-system requirements differ

Under 503A, compounding generally must be based on a valid prescription for an identified individual patient. Federal law permits limited anticipatory compounding before the prescription is received, but the pathway is still organized around patient-specific dispensing rather than general inventory.

A 503B outsourcing facility may compound with or without patient-specific prescriptions and can supply office stock when the applicable conditions are met. It must comply with current good manufacturing practice requirements, register and re-register with FDA, report certain product information, and report adverse events.

That does not make every 503B product superior for every use. It means the facility operates under a different set of federal production, inspection, and reporting requirements.

FDA registration is a checkpoint, not a clean bill of health

FDA publishes a current registered-outsourcing-facility list with the facility’s registration and inspection information. The table can also show whether a Form 483 was issued, whether a recall was conducted, and the status of an action based on the last inspection.

FDA explicitly says that registration does not mean the agency has determined that the facility complies with CGMP or that its products meet every condition of section 503B. FDA also notes that an inspection cannot guarantee that drugs from a facility are safe.

For a 503A pharmacy, verify the pharmacy and prescriber through the relevant state licensing authorities. For a 503B source, verify the exact geographic facility—not only the parent company—and review the current FDA entry and inspection details.

Check the date on every registration and inspection record. A facility can withdraw, fail to re-register, change status, or have an open regulatory action.

The GLP-1 question does not end with 503A or 503B

As of this page’s July 24, 2026 review, FDA says semaglutide and tirzepatide do not appear on the FDA drug-shortage list or the 503B bulks list. FDA also says its shortage-related enforcement-discretion periods for 503A and 503B compounders have ended.

FDA separately proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list after finding no clinical need for outsourcing facilities to compound them from bulk drug substances. A proposal, shortage status, and a patient-specific medical need are different legal and clinical questions.

Ask the provider to name the exact product, the exact facility that compounds it, whether the facility is operating under 503A or 503B, and the current basis for compounding that drug. Then compare the answer with the FDA-approved options and current FDA notices rather than relying on a “503B” badge alone.

Common questions

Answers to clarify the comparison

Is a 503B outsourcing facility the same as a compounding pharmacy?

Not necessarily. FDA says a 503B outsourcing facility is not required to be a licensed pharmacy, although compounding must occur by or under the direct supervision of a licensed pharmacist. Some entities may also hold state pharmacy licenses.

Is a drug from a 503B facility FDA approved?

No. Compounded drugs from outsourcing facilities are not FDA approved and do not undergo the same premarket review as approved products.

Does FDA registration mean a 503B facility passed inspection?

No. Registration places the facility on FDA’s list and into a risk-based inspection framework, but it does not establish compliance. Review the exact facility’s current registration, inspection, Form 483, recall, and action information.

Primary sources

Read the official material behind this page

Health information is educational and does not diagnose, determine eligibility, or replace product labeling and care from a qualified professional.